Naseem Amin
Chairman bei BELLEROPHON THERAPEUTICS, INC.
Vermögen: 16 344 $ am 31.03.2024
Profil
Naseem Amin is currently the Chief Executive Officer & Director at Orphalan SA since 2017 and the Chairman at Bellerophon Therapeutics, Inc. since 2015.
Previously, he served as the Chairman of Open House London Ltd.
and as the Executive Chairman of Arix Bioscience Plc from 2020 to 2021.
He also held positions at Baxter Healthcare Corp.
as Director-Medical Marketing & Portfolio Strategy, at Smith & Nephew plc as Chief Scientific Officer from 2009 to 2014, at Genzyme Corp.
as Head-International Business Development from 1999 to 2005, at Advent Venture Partners LLP as Venture Partner from 2015 to 2019, and at Biogen Idec Ltd.
as Senior Vice President-Business Development from 2005 to 2009.
Dr. Amin obtained an MBA from Kellogg School of Management and a doctorate from UCL Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.06.2023 | 291 865 ( 2,39% ) | 16 344 $ | 31.03.2024 |
Aktive Positionen von Naseem Amin
| Unternehmen | Position | Beginn |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Chairman | 26.05.2021 |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Chief Executive Officer | 01.01.2017 |
Ehemalige bekannte Positionen von Naseem Amin
| Unternehmen | Position | Ende |
|---|---|---|
| ARIX BIOSCIENCE PLC | Chairman | 30.04.2021 |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 31.12.2019 |
| SMITH & NEPHEW PLC | Chief Tech/Sci/R&D Officer | 01.01.2014 |
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Corporate Officer/Principal | 01.01.2009 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2005 |
Ausbildung von Naseem Amin
| Kellogg School of Management | Masters Business Admin |
| UCL Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SMITH & NEPHEW PLC | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| Private Unternehmen | 6 |
|---|---|
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
Open House London Ltd.
 Open House London Ltd. RestaurantsConsumer Services Open House London Ltd. was founded in 2013 and operates restaurants. The non-profit company is based in London, UK. | Consumer Services |
Orphalan SA
Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Health Technology |
